US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.88

+0.19150.49%

Volume:49.35K

Turnover:1.92M

Market Cap:354.60M

PE:- -

High:38.94

Open:38.78

Low:38.66

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.65

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Kura Oncology Reports First Quarter 2026 Financial Results

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Press Release: Immatics Announces First Quarter 2026 Financial Results and Business Update

Cellectis Reports Financial Results for the First Quarter 2026

Alpha Tau Completes Patient Enrollment for U.S. Clinical Trial of Novel Radiotherapy

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Immunocore reports first quarter financial results and provides a business update

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Immutep Quarterly Activities Report Q3 FY26

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Accent Trial Mature Data Presented at International Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ORR/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8815,"timestamp":1787601600000,"preClose":38.69,"halted":0,"volume":49353,"delay":0,"changeRate":0.0049495993796848,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Pre-Mkt","change":0.1915,"latestTime":"08-25 04:18:24 EDT","open":38.78,"high":38.935,"low":38.66,"amount":1915913.762742,"amplitude":0.007108,"askPrice":42.31,"askSize":100,"bidPrice":34.3,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":38.8815,"sharesOutstanding":12900000,"nav":38.62,"aum":352214400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"volumeRatio":0.650059,"impliedVol":0.1458,"impliedVolPercentile":0.538},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.650059,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.007108,"preClose":38.69,"low":38.66,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8815,"eps":0,"divideRate":0,"volume":49353,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635725578","title":"Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725578","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725578?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:10","pubTimestamp":1778789400,"startTime":"0","endTime":"0","summary":"Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295384/0/en/Cardiff-Oncology-Reports-First-Quarter-2026-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","PFS","BK4211","CEO","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","ORR","ET","BK4590","BK4588","SCD","BK4144","BK4585","BK4202","BK4561","BK4081","CR","NCI","BK4161","PTA","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786966","title":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786966?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May  13, 2026  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293836/37149/en/PDS-Biotech-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Programs-and-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4231","XBI","PDS","PFS","BK4195","BK4581","ORR","ADC","BK4080","BK4092","BK4585","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223869","title":"Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223869?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619780,"startTime":"0","endTime":"0","summary":"-- Announced encouraging preliminary safety and efficacy data across all. -- Announced publication in Cancer Discovery highlighting preclinical data. demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor. -- Clinical readouts expected in the second half of 2026 across all three. -- Cash runway expected to fund operations into 2028. SOUTH SAN FRANCISCO, Calif., May 12, 2026  -- BridgeBio Oncology Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3K<ALPHA> activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppressi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","LU2360107325.USD","LU1861214812.USD","LU1548497426.USD","ORR","IE00BZ199S13.USD","CRC","LU1854103824.USD","BK4588","BK4211","IE00BFMHRM44.USD","LU2065732104.USD","LU1861219969.SGD","BBOT","PFS","BK4097","ON","LU1854104046.USD","LU1978683503.SGD","IE00BD6J9T35.USD","LU1720051017.SGD","LU2298322129.HKD","BK4195","PR","BK4605","LU0456854461.SGD","BK4512","LU1861215975.USD","LU1861220033.SGD","LU0348723411.USD","BK4141","BK4139","BK4213","LU0124384867.USD","LU0266512127.USD","LU1720051108.HKD","BK4585","PRGS","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240536","title":"Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240536","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240536?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trialsDENALI Phase 2 tria","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293397/0/en/Zentalis-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Clinical-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","LU2065732104.USD","PROC","PRGS","PFS","BK4080","BK4231","ADC","BK4007","ORR","BK4211","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242093","title":"Kura Oncology Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242093","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242093?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616120,"startTime":"0","endTime":"0","summary":"– $5.8 million in KOMZIFTI (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and comb","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293355/35186/en/Kura-Oncology-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ORR","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219035","title":"PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219035?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human reza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292786/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4139","ODD","PMVP","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634451218","title":"Press Release: Immatics Announces First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634451218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634451218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"-- SUPRAME Phase 3 interim and final analysis for PRAME cell therapy,anzu-cel, expected to be triggered in 2026, advancing toward the. -- Multiple key clinical data sets expected in 2026 across the portfolio,including four clinical-stage cell therapy and bispecific candidates. targeting cutaneous and uveal melanoma, gynecologic cancers (ovarian and. uterine), head and neck cancer, and other solid tumor indications. -- Phase 1 data readout with second-generation PRAME cell therapy,IMA203CD8, to be presented at the 2026 ASCO meeting, focusing on. -- Phase 1b clinical data from PRAME bispecific, IMA402, as monotherapy and. initial data in combination with an immune checkpoint inhibitor at RP2D. bispecifics, IMA402 targeting PRAME and IMA401 targeting MAGEA4/8 in. -- Cash and cash equivalents as well as other financial assets of $521.5. million1  as of March 31, 2026; cash reach projected. Anzu-cel , previously called IMA203, is Immatics' lead PRAME cell therapy and is expected to be the C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","IMTX","PFS","BK4211","BK4139","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230959","title":"Cellectis Reports Financial Results for the First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230959?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:30","pubTimestamp":1778531400,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 tr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292381/0/en/Cellectis-Reports-Financial-Results-for-the-First-Quarter-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","BK4187","IE00B66KJ199.SGD","ORR","LU2065731478.USD","IE0031619046.USD","LU0963586101.USD","BK4139","BK4161","CLLS","IE00B7SZL793.SGD","CR","CRS","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109158909","title":"Alpha Tau Completes Patient Enrollment for U.S. Clinical Trial of Novel Radiotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1109158909","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109158909?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:12","pubTimestamp":1778245934,"startTime":"0","endTime":"0","summary":"Israeli medical company Alpha Tau Medical Ltd. announced today that it has completed enrollment of all 88 patients for its U.S. multicenter pivotal clinical trial (ReSTART) evaluating the novel...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145122","title":"Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145122","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145122?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245200,"startTime":"0","endTime":"0","summary":"- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3291075/0/en/Alpha-Tau-Completes-Patient-Enrollment-in-its-U-S-Pivotal-Skin-Cancer-Study-Advancing-Towards-Goal-of-FDA-Approval-of-Alpha-DaRT-to-Treat-Recurrent-Cutaneous-Squamous-Cell-Carcinom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","ORR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182528","title":"Immunocore reports first quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182528","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633182528?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065200,"startTime":"0","endTime":"0","summary":"Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: K","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288641/0/en/Immunocore-reports-first-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","ATOM","BK4211","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","LU2413666699.HKD","PFS","ALT","BK4533","BK4599","BK4585","IND","LU1721428933.USD","IE00B7SZL793.SGD","IE0031619046.USD","BK4195","BK4121","CRS","LU0963586101.USD","LU2211817866.USD","BK4548","LU2413666426.HKD","BK4007","LU1093756325.SGD","BK4147","ORR","BK4567","LU1878469433.USD","LU0347712357.USD","IE00B19Z4B17.USD","BK4207","CM","IE00B5TLWC47.USD","BK4006","BK4588","MTD","LU1093756168.USD","LU2065731478.USD","BK4187","BK4139","IE00B66KJ199.SGD","PROC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633240359","title":"Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633240359","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633240359?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011500,"startTime":"0","endTime":"0","summary":"FDA Breakthrough Therapy designation granted tozovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288234/0/en/Relay-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","USA","BK4563","RLAY","TAT","BK4139","BK4195","IE00BHPRN162.USD","ORR","BK4135","WT","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633791044","title":"Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633791044","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633791044?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982400,"startTime":"0","endTime":"0","summary":"Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287628/0/en/Zentalis-Pharmaceuticals-Announces-First-Patient-Dosed-in-ASPENOVA-Phase-3-Trial-of-Azenosertib-in-Patients-with-Cyclin-E1-Positive-Platinum-Resistant-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PFS","BK4195","ORR","PROC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633338917","title":"Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633338917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633338917?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:30","pubTimestamp":1777980600,"startTime":"0","endTime":"0","summary":"paclitaxel alone as well as clear signals of a survival benefit in a. Phase 2/3 study of patients with biliary tract cancer ; tovecimig. previously met the primary endpoint of overall response rate .-- Tovecimig received Orphan Drug Designation in April and the Company. intends to meet with the FDA in advance of its planned BLA submission. -- The Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific. antibody) has been selected for a poster presentation at the American. three deep responses  in patients treated in the. post-checkpoint inhibitor setting; cohort expansions in these indications. -- The Phase 1 study for CTX-10726  has. \"In the post-checkpoint inhibitor setting where treatment alternatives are also critically needed, we have ongoing studies with very two promising candidates. Our novel PD-1 x PD-L1 checkpoint inhibitor CTX-8371 continues to demonstrate strong and durable clinical activity and we look forward to presenting dose-escalation and early expansion co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BTC","CMPX","BK4139","ORR","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637961","title":"Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637961","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637961?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:31","pubTimestamp":1777552260,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, April  30, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284876/0/en/Can-Fite-Reports-Positive-Phase-2a-Data-with-Namodenoson-in-Pancreatic-Cancer-35-of-Patients-Remain-on-Therapy-Including-One-Beyond-16-Months.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","PK","BK4211","PFS","BK4195","HCC","ORR","BK4006","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634961","title":"Immutep Quarterly Activities Report Q3 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634961?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284806/0/en/Immutep-Quarterly-Activities-Report-Q3-FY26.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0053666078.USD","LU0210528500.USD","ORR","L","LU2487616109.SGD","BK4107","IMMP","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630525317","title":"Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630525317","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630525317?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:01","pubTimestamp":1777320060,"startTime":"0","endTime":"0","summary":"Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281996/0/en/Erasca-Announces-Positive-Preliminary-Phase-1-Dose-Escalation-Data-for-Potentially-Best-in-Class-Pan-RAS-Molecular-Glue-ERAS-0015-in-KRAS-Mutant-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCO","PD","BK4218","LU1169589451.USD","ORR","PK","BK4023","BK4187","CRC","ERAS","IE00B66KJ199.SGD","LU0566484027.USD","BK4181","LU0266512127.USD","CN","ADME","BK4139","IE00B19Z4B17.USD","BK4539","LU1169590202.USD","LU0456854461.SGD","LU1559883803.SGD","BK4213","IE00B7SZL793.SGD","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395644","title":"Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395644","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395644?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289400,"startTime":"0","endTime":"0","summary":"Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281512/0/en/Tovecimig-Demonstrates-Statistically-Significant-Benefit-in-COMPANION-002-Randomized-Phase-2-3-Study-in-Patients-with-Biliary-Tract-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BTC","BK4195","ORR","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629893041","title":"Accent Trial Mature Data Presented at International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2629893041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629893041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:45","pubTimestamp":1776861900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meetingThe ACCENT trial investigates ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278983/0/en/Accent-Trial-Mature-Data-Presented-at-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4211","PFS","BK4195","INNMF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":134,"code":"91000000","status":"200"}]}}